Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Recent Clinical Experience with Oncolytic Viruses

Author(s): O. G. Donnelly, F. Errington-Mais, R. Prestwich, K. Harrington, H. Pandha, R. Vile and A. A. Melcher

Volume 13, Issue 9, 2012

Page: [1834 - 1841] Pages: 8

DOI: 10.2174/138920112800958904

Price: $65

Open Access Journals Promotions 2
conference banner
Abstract

There has been interest in using viruses to treat cancer for over a century. Recent clinical efforts, driven on by significant preclinical advances, have focussed on the safety of using replication-competent viruses. Recently published clinical trials of six oncolytic viruses (adenovirus, reovirus, measles, herpes simplex, Newcastle disease virus and vaccinia) have added to the accumulating data that endorse oncolytic viruses as a safe and well tolerated treatment approach. Conclusive evidence of efficacy remains to be demonstrated, but randomised clinical trials are now underway.

Keywords: Oncolytic virus, adenovirus, measles, reovirus, vaccinia, cancer, replication-competent viruses


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy